ym 872 has been researched along with quinoxalines in 37 studies
| Studies (ym 872) | Trials (ym 872) | Recent Studies (post-2010) (ym 872) | Studies (quinoxalines) | Trials (quinoxalines) | Recent Studies (post-2010) (quinoxalines) |
|---|---|---|---|---|---|
| 41 | 0 | 5 | 9,887 | 625 | 3,095 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 11 (29.73) | 18.2507 |
| 2000's | 21 (56.76) | 29.6817 |
| 2010's | 5 (13.51) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kawasaki-Yatsugi, S; Koshiya, K; Ni, JW; Sakamoto, S; Shimizu-Sasamata, M; Shishikura, JI; Takahashi, M; Toya, T; Yamaguchi, T; Yatsugi, SI | 1 |
| Ichiki, C; Kawasaki-Yatsugi, S; Minematsu, K; Shimizu-Sasamata, M; Takahashi, M; Toya, T; Yamaguchi, T; Yatsugi, S | 1 |
| Kawasaki-Yatsugi, S; Monette, R; Morley, P; Murray, CL; Small, DL | 1 |
| Inami, H; Kohara, A; Ohno, K; Okada, M; Sakamoto, S; Shimizu-Sasamata, M; Shishikura, J; Takahashi, M; Tsutsumi, R; Yamaguchi, T | 1 |
| Kano, T; Lo, EH; Moskowitz, MA; Rogowska, J; Shimizu-Sasamata, M; Wolf, GL | 1 |
| Håberg, A; Haraldseth, O; Hjelstuen, M; Takahashi, M; Yamaguchi, T | 1 |
| Ichiki, C; Kawasaki-Yatsugi, S; Koshiya, K; Ni, JW; Shimizu-Sasamata, M; Takahashi, M; Toya, T; Yamaguchi, T; Yatsugi, SI | 1 |
| Ni, JW; Shimizu-Sasamata, M; Takahashi, M; Yamaguchi, T; Yatsugi, S | 1 |
| Gyermek, L; Kawasaki-Yatsugi, S; Lee, C; Nishiyama, T; Yamaguchi, T | 4 |
| Ichiki, C; Kawasaki-Yatsugi, S; Minematsu, K; Shimizu-Sasamata, M; Takahashi, M; Yamaguchi, T; Yatsugi, S | 1 |
| Lo, EH; Moskowitz, MA; Sasamata, M | 1 |
| Gyermek, L; Hanaoka, K; Kawasaki-Yatsugi, S; Lee, C; Nishiyama, T; Yamaguchi, T | 1 |
| Sareen, D | 1 |
| Hagimura, N; Ishiuchi, S; Kurihara, H; Miwa, A; Nakazato, Y; Okado, H; Ozawa, S; Sasaki, T; Tamura, M; Tsuzuki, K; Yamada, N; Yoshida, Y | 1 |
| Miyata, K; Sasamata, M; Suzuki, M | 1 |
| Kawasaki-Yatsugi, S; Kohara, A; Ni, JW; Okada, M; Sakamoto, S; Shimizu-Sasamata, M; Shishikura, J; Takahashi, M; Yamaguchi, T; Yatsugi, S | 1 |
| Miyata, K; Sasamata, M; Suzuki, M; Terai, K; Yamaguchi, T; Yatsugi, Si | 1 |
| Asakura, T; Atsumi, T; Furukawa, T; Hoshino, S; Kobayashi, S; Takahashi, M; Teramoto, A | 1 |
| Arendt-Nielsen, L; Sumikura, H | 1 |
| Asakura, T; Atsumi, T; Furukawa, T; Hoshino, S; Kobayashi, S; Takahashi, M; Teramoto, A; Yamamoto, Y | 1 |
| Hanaoka, K; Kawasaki-Yatsugi, S; Nishiyama, T; Yamaguchi, T | 1 |
| Endou, H; Hashimoto, T; Huang, XL; Kamimura, H; Minematsu, T; Narikawa, S; Usui, T | 1 |
| Funatsu, M; Hashimoto, T; Imai, H; Kamimura, H; Minematsu, T; Sohda, KY; Suzuki, K; Suzumura, K; Usui, T | 1 |
| Hashimoto, T; Imai, H; Kamimura, H; Minematsu, T; Sohda, KY; Usui, T | 1 |
| Hara, H; Kodama, M; Kuroda, S; Matsumoto, Y; Wake, Y; Yamada, N | 1 |
| Barr, GA; King, TE | 1 |
| Nishiyama, T | 1 |
| Aoki, T; Hashimoto, T; Kamimura, H; Minematsu, T; Usui, T | 1 |
| Hashimoto, T; Kamimura, H; Minematsu, T; Usui, T | 1 |
| Aihara, M; Ishiuchi, S; Ohtani, T; Watanabe, T | 1 |
| Bartlett, CA; Chiha, W; Fitzgerald, M; Giacci, MK; Harvey, AR; Hodgetts, SI; O'Hare Doig, RL; Smith, NM; Yates, NJ | 1 |
| Fehily, B; Fitzgerald, M; Gavriel, N; Giacci, MK; Gough, AH; Gray, CGG; Milbourn, HR; Toomey, LM | 1 |
| Bartlett, CA; Fitzgerald, M; Gopalasingam, G; Majimbi, M; Rodger, J; Toomey, LM | 1 |
| Bartlett, CA; Fitzgerald, M; Gavriel, N; Gopalasingam, G; Majimbi, M; McGonigle, T; Rodger, J; Toomey, LM | 1 |
4 review(s) available for ym 872 and quinoxalines
| Article | Year |
|---|---|
[New method for evaluating the effects of neuroprotective therapy in the hemodynamic penumbra].
Topics: Animals; Brain Ischemia; Endothelium, Vascular; Hemodynamics; Imidazoles; Mice; Mice, Knockout; Neuroprotective Agents; Nitric Oxide Synthase; Quinoxalines; Rats; Receptors, AMPA; Tomography, X-Ray Computed | 2000 |
Neuroprotective agents in acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Animals; Antioxidants; Calcium Channel Blockers; Chlormethiazole; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Excitatory Amino Acid Antagonists; Excitatory Amino Acids; Forecasting; GABA Modulators; Guanidines; Humans; Imidazoles; Middle Aged; Naltrexone; Narcotic Antagonists; Neuroprotective Agents; Pipecolic Acids; Piperidines; Quinoxalines; Rats; Receptors, N-Methyl-D-Aspartate; Reperfusion Injury; Stroke; Thiazoles | 2002 |
YM872: a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist.
Topics: Animals; Brain Ischemia; Cats; Clinical Trials, Phase I as Topic; Disease Models, Animal; Excitatory Amino Acid Antagonists; Humans; Imidazoles; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Quinoxalines; Rats; Receptors, AMPA; Solubility; Stroke | 2002 |
Limiting oxidative stress following neurotrauma with a combination of ion channel inhibitors.
Topics: Animals; Calcium; Central Nervous System; Humans; Imidazoles; Myelin Sheath; Nerve Degeneration; Oxidative Stress; Piperazines; Quinoxalines; Reactive Oxygen Species | 2017 |
33 other study(ies) available for ym 872 and quinoxalines
| Article | Year |
|---|---|
YM872, a novel selective alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, reduces brain damage after permanent focal cerebral ischemia in cats.
Topics: Animals; Brain; Brain Ischemia; Cats; Cerebral Cortex; Corpus Striatum; Imidazoles; Male; Neuroprotective Agents; Quinoxalines; Receptors, AMPA; Regional Blood Flow | 1998 |
A novel AMPA receptor antagonist, YM872, reduces infarct size after middle cerebral artery occlusion in rats.
Topics: Animals; Arterial Occlusive Diseases; Blood Gas Analysis; Body Temperature; Brain; Brain Ischemia; Cerebral Arteries; Cerebral Infarction; Disease Models, Animal; Dose-Response Relationship, Drug; Imidazoles; Infusions, Intravenous; Kidney; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 1998 |
Neuroprotective effects of a novel AMPA receptor antagonist, YM872.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Cell Survival; Cells, Cultured; Cerebral Cortex; Excitatory Postsynaptic Potentials; Fetus; Glucose; Hippocampus; Imidazoles; In Vitro Techniques; Microscopy, Confocal; Neurons; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 1998 |
In-vitro characterization of YM872, a selective, potent and highly water-soluble alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Binding, Competitive; Buffers; Cells, Cultured; Excitatory Amino Acid Antagonists; Hippocampus; Imidazoles; Kainic Acid; Male; Neuroprotective Agents; Oocytes; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Solubility; Xenopus laevis | 1998 |
YM872, a highly water-soluble AMPA receptor antagonist, preserves the hemodynamic penumbra and reduces brain injury after permanent focal ischemia in rats.
Topics: Animals; Brain; Brain Ischemia; Cerebrovascular Circulation; Hemodynamics; Imidazoles; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA; Solubility; Time Factors; Tomography, X-Ray Computed; Water | 1998 |
Neuroprotective effect of the novel glutamate AMPA receptor antagonist YM872 assessed with in vivo MR imaging of rat MCA occlusion.
Topics: Animals; Arterial Occlusive Diseases; Cerebral Arterial Diseases; Drug Evaluation, Preclinical; Imidazoles; Linear Models; Magnetic Resonance Imaging; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Wistar; Receptors, AMPA | 1998 |
Neuroprotective efficacy of YM872, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, after permanent middle cerebral artery occlusion in rats.
Topics: Animals; Brain Ischemia; Cerebral Arteries; Excitatory Amino Acid Antagonists; Imidazoles; Male; Motor Activity; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA | 1998 |
Effects of YM872 on atrophy of substantia nigra reticulata after focal ischemia in rats.
Topics: Animals; Arterial Occlusive Diseases; Atrophy; Body Temperature; Body Weight; Brain Ischemia; Cerebral Infarction; Imidazoles; Male; Neurologic Examination; Neuroprotective Agents; Quinoxalines; Rats; Rats, Inbred F344; Receptors, AMPA; Substantia Nigra | 1998 |
The spinal antinociceptive effects of a novel competitive AMPA receptor antagonist, YM872, on thermal or formalin-induced pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Dose-Response Relationship, Drug; Formaldehyde; Imidazoles; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Spinal Cord | 1999 |
Analgesic interaction between intrathecal midazolam and glutamate receptor antagonists on thermal-induced pain in rats.
Topics: 2-Amino-5-phosphonovalerate; Animals; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; GABA Modulators; Imidazoles; Injections, Spinal; Midazolam; Motor Activity; Pain; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate | 1999 |
The systemically administered competitive AMPA receptor antagonist, YM872, has analgesic effects on thermal or formalin-induced pain in rats.
Topics: Analgesics, Non-Narcotic; Animals; Behavior, Animal; Binding, Competitive; Formaldehyde; Hot Temperature; Imidazoles; Injections, Intraperitoneal; Male; Motor Activity; Nociceptors; Pain; Pain Measurement; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA | 1999 |
Neuroprotective effects of an AMPA receptor antagonist YM872 in a rat transient middle cerebral artery occlusion model.
Topics: Animals; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorders; Imidazoles; Male; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Reperfusion Injury | 2000 |
The analgesic interaction between intrathecal clonidine and glutamate receptor antagonists on thermal and formalin-induced pain in rats.
Topics: Adrenergic alpha-Agonists; Analgesics, Non-Narcotic; Animals; Clonidine; Dose-Response Relationship, Drug; Drug Interactions; Excitatory Amino Acid Antagonists; Imidazoles; Injections, Spinal; Pain; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Valine | 2001 |
Synergistic analgesic effects of intrathecal midazolam and NMDA or AMPA receptor antagonists in rats.
Topics: 2-Amino-5-phosphonovalerate; Adjuvants, Anesthesia; Animals; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Formaldehyde; Imidazoles; Male; Midazolam; Neuroprotective Agents; Pain Measurement; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Receptors, GABA-A; Receptors, N-Methyl-D-Aspartate | 2001 |
Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells.
Topics: Adenoviridae; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Apoptosis; Brain Neoplasms; Calcium; Cell Movement; Genetic Vectors; Glioblastoma; Humans; Imidazoles; Mice; Mice, Nude; Permeability; Quinoxalines; Receptors, AMPA; Tumor Cells, Cultured | 2002 |
Neuroprotective effects of YM872 coadministered with t-PA in a rat embolic stroke model.
Topics: Animals; Carotid Artery Thrombosis; Cerebral Infarction; Fibrinolytic Agents; Imidazoles; Infusions, Intravenous; Male; Models, Animal; Motor Activity; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Tissue Plasminogen Activator | 2003 |
Effect of AMPA receptor antagonist YM872 on cerebral hematoma size and neurological recovery in the intracerebral hemorrhage rat model.
Topics: Animals; Atrophy; Brain Edema; Brain Infarction; Cerebral Hemorrhage; Collagenases; Dose-Response Relationship, Drug; Hematoma; Heparin; Imidazoles; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2003 |
The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats.
Topics: Animals; Body Temperature; Brain Edema; Brain Injuries; Cerebral Cortex; Glutamic Acid; Imidazoles; Male; Models, Animal; Neuroprotective Agents; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Recovery of Function | 2003 |
MAC reduction after intrathecal coadministration of GABA(A) agonist and glutamate antagonist in rats.
Topics: 2-Amino-5-phosphonovalerate; Anesthetics, Inhalation; Animals; Drug Synergism; Excitatory Amino Acid Antagonists; GABA Agonists; Imidazoles; Injections, Spinal; Male; Methyl Ethers; Muscimol; N-Methylaspartate; Pain; Pulmonary Alveoli; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Sevoflurane | 2003 |
The glutamate AMPA receptor antagonist, YM872, attenuates regional cerebral edema and IgG immunoreactivity following experimental brain injury in rats.
Topics: Animals; Body Water; Brain; Brain Edema; Brain Injuries; Imidazoles; Immunoglobulin G; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA | 2003 |
Spinal neurotoxicity and tolerance after repeated intrathecal administration of YM 872, an AMPA receptor antagonist, in rats.
Topics: Analgesics; Animals; Behavior, Animal; Drug Tolerance; Imidazoles; Injections, Spinal; Male; Pain Measurement; Pain Threshold; Quinoxalines; Rats; Rats, Sprague-Dawley; Reaction Time; Receptors, AMPA; Spinal Cord; Tail | 2004 |
Characterization of the renal tubular transport of zonampanel, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor antagonist, by human organic anion transporters.
Topics: Biological Transport; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; Humans; Imidazoles; Kidney Tubules; Organic Anion Transporters; Quinoxalines; Receptors, AMPA | 2004 |
Application of LC-NMR for characterization of rat urinary metabolites of zonampanel monohydrate (YM872).
Topics: Animals; Chromatography, Liquid; Imidazoles; Magnetic Resonance Spectroscopy; Male; Quinoxalines; Rats; Rats, Sprague-Dawley | 2004 |
Identification of metabolites of [14C]zonampanel, an a-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, following intravenous infusion in healthy volunteers.
Topics: Adolescent; Adult; Carbon Radioisotopes; Humans; Imidazoles; Injections, Intravenous; Male; Quinoxalines; Receptors, AMPA | 2005 |
Effect of YM872, a selective and highly water-soluble AMPA receptor antagonist, in the rat kindling and rekindling model of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Imidazoles; Kindling, Neurologic; Male; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Time Factors | 2006 |
Spinal cord ionotropic glutamate receptors function in formalin-induced nociception in preweaning rats.
Topics: Age Factors; Animals; Animals, Suckling; Behavior, Animal; Dizocilpine Maleate; Imidazoles; Motor Activity; Pain; Pain Measurement; Quinoxalines; Rats; Rats, Long-Evans; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Spinal Cord | 2007 |
Interaction between a NMDA receptor antagonist, AP-5 and an AMPA receptor antagonist, YM 872 in antinociception in the spinal cord.
Topics: 2-Amino-5-phosphonovalerate; Acute Disease; Analgesics; Animals; Chronic Disease; Dose-Response Relationship, Drug; Drug Synergism; Excitatory Amino Acid Antagonists; Imidazoles; Male; Pain; Pain Measurement; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, N-Methyl-D-Aspartate; Spinal Cord | 2008 |
Role of organic anion transporters in the pharmacokinetics of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in rats.
Topics: Animals; Cell Line; Cimetidine; Excitatory Amino Acid Antagonists; Humans; Imidazoles; LLC-PK1 Cells; Male; Organic Anion Transporters; Probenecid; Quinoxalines; Rats; Rats, Sprague-Dawley; Receptors, AMPA; Swine | 2008 |
Characterization of renal tubular apical efflux of zonampanel, an alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptor antagonist, in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Glutarates; Humans; Imidazoles; Kidney Tubules; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Organic Anion Transporters, Sodium-Independent; Quinoxalines; Receptors, AMPA; Transport Vesicles | 2008 |
Enhanced antitumor effect of YM872 and AG1296 combination treatment on human glioblastoma xenograft models.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Therapy, Combination; Glioblastoma; Humans; Imidazoles; In Vitro Techniques; Mice; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Quinoxalines; Receptors, AMPA; Receptors, Platelet-Derived Growth Factor; Transplantation, Heterologous; Treatment Outcome; Tyrphostins | 2013 |
Specific ion channels contribute to key elements of pathology during secondary degeneration following neurotrauma.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Disease Models, Animal; Female; Imidazoles; Macrophages; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Optic Nerve Injuries; Oxidative Stress; Piperazines; Purinergic P2X Receptor Antagonists; Quinoxalines; Random Allocation; Ranvier's Nodes; Rats; Receptors, AMPA; Receptors, Purinergic P2X7 | 2017 |
Comparison of ion channel inhibitor combinations for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium-Binding Proteins; Cell Adhesion Molecules, Neuronal; Disease Models, Animal; Drug Delivery Systems; Drug Therapy, Combination; Ectodysplasins; Female; Imidazoles; Ion Channels; Macrophages; Microfilament Proteins; Microglia; Nerve Degeneration; Nystagmus, Optokinetic; Oligodendrocyte Transcription Factor 2; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Rosaniline Dyes; Tubulin | 2019 |
Comparing modes of delivery of a combination of ion channel inhibitors for limiting secondary degeneration following partial optic nerve transection.
Topics: Animals; Calcium Channel Blockers; Calcium Channels; Drug Therapy, Combination; Female; Imidazoles; Myelin Sheath; Nerve Degeneration; Optic Nerve; Optic Nerve Injuries; Piperazines; Quinoxalines; Rats; Receptors, AMPA; Receptors, Purinergic P2X7; Rosaniline Dyes | 2019 |